Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)

PURPOSE: Recombinant activated factor VII (rFVIIa; NovoSeven(®) RT; Novo Nordisk A/S, Bagsvaerd, Denmark) is approved in the United States for the treatment of bleeding and perioperative management in congenital hemophilia with inhibitors (CHwI), acquired hemophilia (AH), congenital factor VII (FVII...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajpurkar, Madhvi, Croteau, Stacy E, Boggio, Lisa, Cooper, David L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757140/
https://www.ncbi.nlm.nih.gov/pubmed/31572039
http://dx.doi.org/10.2147/JBM.S219573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757140/
https://www.ncbi.nlm.nih.gov/pubmed/31572039
http://dx.doi.org/10.2147/JBM.S219573

Ejemplares similares